89.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$89.78
Aprire:
$90.21
Volume 24 ore:
2.62M
Relative Volume:
0.62
Capitalizzazione di mercato:
$51.82B
Reddito:
$6.30B
Utile/perdita netta:
$1.07B
Rapporto P/E:
48.84
EPS:
1.8406
Flusso di cassa netto:
$1.09B
1 W Prestazione:
-0.34%
1M Prestazione:
+0.33%
6M Prestazione:
+5.49%
1 anno Prestazione:
+11.04%
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, MDT, SYK, BSX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
|
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Azimuth Capital Investment Management LLC Decreases Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
B. Metzler seel. Sohn & Co. AG Lowers Position in Edwards Lifesciences Corporation $EW - MarketBeat
Nykredit A S Makes New $20.64 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit 2026 - BioSpace
Empowered Funds LLC Buys New Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW) SVP, Corporate Controller Andrew Dahl Sells 544 Shares - GuruFocus
NS Partners Ltd Reduces Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Van ECK Associates Corp Decreases Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE:EW) SVP Sells 544 Shares of Stock - MarketBeat
Edwards Lifesciences SVP sells $49,533 in stock - Investing.com
Breadth Narrows, Software Shines; Fortinet, Edwards Lifesciences, UBS In FocusVideoIBD - Investor's Business Daily
Edwards Lifesciences (NYSE: EW) exec plans $49K stock sale - stocktitan.net
Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock - Barchart.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
24,532 Shares in Edwards Lifesciences Corporation $EW Purchased by Kingsview Wealth Management LLC - MarketBeat
19,972 Shares in Edwards Lifesciences Corporation $EW Purchased by United Capital Financial Advisors LLC - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Alyeska Investment Group L.P. - MarketBeat
Wellington Management Group LLP Lowers Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Jefferies Financial Group Inc. Invests $3.58 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW) Insider Sells 2,644 Shares; Valuation Remains Fairly Valued - GuruFocus
Edwards Lifesciences (NYSE:EW) VP Sells 2,644 Shares - MarketBeat
Edwards Lifesciences' Donald E. Bobo, Jr. to Retire as Corporate VP; Successor Search Underway - TradingView
MASTERINVEST Kapitalanlage GmbH Purchases New Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Insider Move: Daveen Chopra Exercises Options, Realizing $551K At Edwards Lifesciences - benzinga.com
Edwards Lifesciences (NYSE: EW) exec may sell 1,240 shares - stocktitan.net
Hsbc Holdings PLC Sells 144,364 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Legal & General Group Plc Buys New Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Commerce Bank Buys Shares of 34,501 Edwards Lifesciences Corporation $EW - MarketBeat
Daiichi Life Insurance Co. Ltd. Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Great Lakes Advisors LLC Invests $1.25 Million in Edwards Lifesciences Corporation $EW - MarketBeat
WealthShield Partners LLC Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by NewEdge Advisors LLC - MarketBeat
40,124 Shares in Edwards Lifesciences Corporation $EW Acquired by Wealthfront Advisers LLC - MarketBeat
Tocqueville Asset Management L.P. Makes New $5.37 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Fairtree Asset Management Pty Ltd Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Bank of New York Mellon Corp Takes Position in Edwards Lifesciences Corporation $EW - MarketBeat
Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event? - Yahoo Finance
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Edwards Lifesciences stock holds gains as Q2 growth supports 2026 outlook - Ad-hoc-news.de
Should You Hold Edwards Lifesciences Stock in Your Portfolio? - Yahoo Finance
Global Cardiovascular Devices Market to Reach $101.6 Billion by 2030, Says BCC Research Analyst - GlobeNewswire
524,490 Shares in Edwards Lifesciences Corporation $EW Acquired by Danske Bank A S - MarketBeat
Edwards Lifesciences (EW) Stock Could Be 1% Above Fair Value On Cash Flow And Earnings - Yahoo Finance
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Here’s How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years - Benzinga
Aristotle Capital Management, LLC's Edwards Lifesciences Corp(EW) Holding History - GuruFocus
Mitsubishi UFJ Asset Management Co. Ltd. Takes $126.12 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Putting Patients at the Heart of Innovation: Voices Across Asia Pacific Help Shape the Future of Structural Heart Care - Yahoo Finance
BlackRock Inc. Acquires New Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock holds steady as analysts see upside - AD HOC NEWS
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):